PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

205 episodes - English - Latest episode: 11 days ago - ★★★★ - 5 ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Science cme medical education cme credits peerview insession inreview immunology transplantation cne
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Episodes

Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

July 12, 2022 23:00 - 1 hour

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TK...

Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

July 08, 2022 23:00 - 1 hour

Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective a...

Nelson Chao, MD, MBA - Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and Treatment

July 08, 2022 23:00 - 51 minutes

Go online to PeerView.com/GBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)—a serious complication arising in the aftermath of hematopoietic stem cell transplantation? In addition to life-threatening organ dysfunction in serious cases, VOD presents additional diagnostic and assessment challenges based on its varied onset time and symptomat...

Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

July 08, 2022 23:00 - 57 minutes

Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on ...

James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

July 06, 2022 23:00 - 53 minutes

Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruc...

Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols

July 04, 2022 23:00 - 56 minutes

Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell ...

Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

June 29, 2022 23:00 - 1 hour

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the lis...

Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

May 27, 2022 23:00 - 27 minutes

Go online to PeerView.com/FSQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of airway hyper-responsiveness in severe uncontrolled asthma. Upon completion of this activity, participants should be better able to: Compare the pathophysiology of airway inflammation with airway hyper-responsiveness (AHR) and their clinical manifestations in patients with severe asthma, Apply insights ...

Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

May 25, 2022 23:00 - 42 minutes

Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–s...

Joseph Diaz, MD- Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life

May 23, 2022 23:00 - 52 minutes

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; althou...

Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World

May 13, 2022 23:00 - 1 hour

Go online to PeerView.com/VMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence. Upon completion of this activity, participants should be better able to: Assess the severity of asthma in pediatric and adult patients according to...

Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine

April 11, 2022 23:00 - 1 hour

Go online to PeerView.com/DRJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to bring modern approaches to the treatment of patients with biliary cancers to your clinical practice? Learn how the treatment paradigm is shifting from conventional chemotherapy to biomarker-guided treatments and immunotherapy in a new event from PeerView and the Cholangiocarcinoma Foundation. Our experts will offer learners a deep dive into ...

Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

April 01, 2022 23:00 - 54 minutes

Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The...

Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

April 01, 2022 23:00 - 56 minutes

Go online to PeerView.com/FTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma detail the pathophysiology of severe asthma, with a discussion of the underlying mechanisms behind both type 2 and non–type 2 asthma, and novel and emerging therapies for its treatment. Upon completion of this CE activity, participants will be able to: Discuss unmet treatment needs for patients with severe, uncontrolled asthm...

Paneez Khoury - Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes

February 28, 2022 23:00 - 33 minutes

Go online to PeerView.com/DMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment. Upon completion of this CE activity, participants will be able to: Describe the burden of hypereosinophilic syndrome (HES) on patients, including the consequences of underdiagnosed and unde...

Chris A. Liacouras, MD - Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy

January 31, 2022 23:00 - 1 hour

Go online to PeerView.com/FTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of gastroenterologists (pediatric and adult), allergists/immunologists (pediatric and adult), nurses, NPs, PAs, and other clinicians involved in the management of EoE. Upon completion of this CE activity, participants will be able to: Distinguish signs and symptoms of eosinophilic esophagitis (EoE) a...

Emma Guttman-Yassky, MD, PhD - Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis

January 10, 2022 23:00 - 1 hour

Go online to PeerView.com/AYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts will review the presentation and diagnosis of AD and discuss the current evidence and guidelines for treatment selection for pediatric and adult patients. The faculty will also offer their thoughts on engaging with patients to provide personalized care and improved outcomes. Learn from the data and the experts in this inform...

Evan S. Dellon, MD, MPH - Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

January 06, 2022 23:00 - 1 hour

Go online to PeerView.com/SQH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in eosinophilic esophagitis discuss the diagnosis of pediatric and adult EoE, the current standard of care, and novel and emerging treatments that may be the future of EoE management. Upon completion of this CE activity, participants will be able to: Differentiate signs and symptoms of eosinophilic esophagitis (EoE) among children and ...

R. Sharon Chinthrajah, MD - Fulfilling Unmet Treatment Needs for Patients With IgE-Mediated Food Allergies: An Animated Exploration of Emerging Targeted Therapy

December 09, 2021 23:00 - 25 minutes

Go online to PeerView.com/KHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies. Upon completion of this accredited CE activity, participants should be better able to: Discuss key limitations associated with current treatment approaches for managing food allergies, Differentiate the mechanisms of a...

Ikuo Hirano, MD - On the Cusp of a New Era in Treatment for Eosinophilic Esophagitis: Expert Insights on the Latest Advances in Targeted Therapy

November 23, 2021 23:00 - 19 minutes

Go online to PeerView.com/AZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies. Upon completion of this CE activity, participants will be able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of eosinophilic esophagitis (EoE), Employ the...

Jonathan A. Bernstein, MD - Visualizing Progress in the Management of Chronic Spontaneous Urticaria: Harnessing the Clinical Potential of New and Novel Therapies to Address Unmet Patient Needs

November 19, 2021 23:00 - 22 minutes

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct...

"Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis"

November 03, 2021 23:00 - 25 minutes

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recen...

Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis

November 03, 2021 23:00 - 25 minutes

Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

October 19, 2021 23:00 - 51 minutes

Go online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options...

Ian Pavord, FMedSci - Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate to Severe Asthma

October 12, 2021 23:00 - 34 minutes

Go online to PeerView.com/DWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma. Upon completion of this accredited CE activity, participants should be better able to: Explain to peers the latest developments i...

Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment

October 11, 2021 23:00 - 51 minutes

Go online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, an...

Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential

October 01, 2021 23:00 - 27 minutes

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate rec...

Jason J. Luke, MD, FACP / Geoffrey T. Gibney, MD - Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease

July 16, 2021 23:00 - 1 hour

Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon comp...

April W. Armstrong, MD, MPH - Beyond TNF Inhibitors: Latest and Emerging Evidence on Novel Cytokine-Modulating Strategies in the Treatment of Moderate to Severe Psoriasis

July 02, 2021 23:00 - 28 minutes

Go online to PeerView.com/FXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses the latest evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis. Upon completion of this accredited CE activity, participants should be better able to: Recognize unmet needs in the treatment of moderate to severe psoriasis, Describe the pathophysiology of psoriasis...

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

June 25, 2021 23:00 - 37 minutes

Go online to PeerView.com/NJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses unmet needs of patients with moderate to severe psoriasis and the clinical potential of targeting the TYK2 pathway as a novel nonbiologic oral therapeutic option. Upon completion of this accredited CE activity, participants should be better able to: Explain the role of the JAK-STAT signaling pathway in the pa...

Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer

June 22, 2021 23:00 - 1 hour

Go online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inh...

Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

June 21, 2021 23:00 - 1 hour

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in c...

Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

June 18, 2021 23:00 - 27 minutes

Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, ph...

Karl E. Anderson, MD - Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

June 02, 2021 23:00 - 31 minutes

Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be exper...

Dara L. Aisner, MD, PhD / Joshua Bauml, MD / Paul A. VanderLaan, MD, PhD - Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC

June 01, 2021 23:00 - 1 hour

Go online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK, ...

Naval Daver, MD - Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team Insights From a Center of Excellence

May 28, 2021 23:00 - 54 minutes

Go online to PeerView.com/BFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD Anders...

John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine

May 14, 2021 23:00 - 35 minutes

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts al...

Corey Cutler, MD, MPH, FRCP(C) & Miguel-Angel Perales, MD - New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics

April 08, 2021 23:00 - 53 minutes

Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should i...

"Corey Cutler, MD, MPH, FRCP(C) & Miguel-Angel Perales, MD - New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics"

April 08, 2021 23:00 - 53 minutes

Titte R. Srinivas, MD, FAST - Optimizing Maintenance Immunosuppressive Therapy in Kidney Transplantation: Examining Current and Future Strategies to Preserve Graft Function and Maximize Long-Term Outcomes

April 01, 2021 23:00 - 28 minutes

Go online to PeerView.com/SDN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses evidence-based strategies to individualize immunosuppressive therapy and optimize long-term outcomes after renal transplantation. Upon completion of this activity, participants should be better able to: Identify risk factors for graft loss and mortality after renal transplantation, Recognize the benefits and l...

Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

March 31, 2021 23:00 - 59 minutes

Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completio...

Ruben A. Mesa, MD, FACP / Jeanne M. Palmer, MD - How to Manage JAK Inhibition in Patients Undergoing HCT: Applying the Latest Clinical Evidence to Improve Patient Outcomes in Myelofibrosis

March 26, 2021 23:00 - 58 minutes

Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decis...

Stella Lee, MD - Improving the Management of Chronic Rhinosinusitis With Nasal Polyps: Practical Strategies for Selecting the Right Patients for Targeted Treatment

March 24, 2021 23:00 - 34 minutes

Go online to PeerView.com/ERM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps (CRS/NP) discusses how to diagnose and manage CRS/NP; identifies patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy; and discusses treatment plans for patients with CRS/NP according to international consensus statements and the latest...

Jason J. Luke, MD, FACP - Expanding the Benefits of Immuno-Oncology to More Patients With Solid Tumors Through Novel Rational Targets and Combinations

March 22, 2021 23:00 - 39 minutes

Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical ...

Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes

March 10, 2021 23:00 - 1 hour

Go online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts...

Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT

March 08, 2021 23:00 - 59 minutes

Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovativ...

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Mapping the New Era in CLL Management: Precision Medicine and Patient Perspectives in Treatment-Naïve and Relapsed Disease

January 29, 2021 23:00 - 1 hour

Go online to PeerView.com/QUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologists, oncologists, and a patient advocate discuss compelling, real-world case scenarios and the practice-changing evidence that continues to support the increasing role of novel therapeutics in CLL. This event also explores the future of CLL care and illustrates how novel combinations and cellular therapy may lead t...

Steven M. Horwitz, MD - Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease

January 22, 2021 23:00 - 1 hour

Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various hema...

Jonathan Corren, MD - Reducing the Burden of Chronic Rhinosinusitis With Nasal Polyps on Patient Quality of Life: An Exploration of Novel and Emerging Biologic Therapy

January 12, 2021 23:00 - 30 minutes

Go online to PeerView.com/XNY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps discusses novel and emerging biologic therapies to improve the quality of life for patients with chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Recognize the burden that chronic rhinosinusitis with nasal polyps (CRS/NP) on ...

Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

January 11, 2021 23:00 - 1 hour

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, research...